©The Author(s) 2019.
World J Gastrointest Oncol. Jul 15, 2019; 11(7): 551-566
Published online Jul 15, 2019. doi: 10.4251/wjgo.v11.i7.551
Published online Jul 15, 2019. doi: 10.4251/wjgo.v11.i7.551
Table 2 Clinicopathologic data for colorectal cancer patients treated with adjuvant chemotherapy
| Clinicopathologic data | Total (n = 130) |
| Median age (range) | 67 (37-88) |
| Male | 79 (60.8) |
| Primary site | |
| Rectum | 60 (46.2) |
| Positive lymph nodes | 76 (58.5) |
| Stage according to AJCC | |
| I | 1 (0.8) |
| II | 54 (41.5) |
| III | 75 (57.7) |
| Histological grade | |
| I + II | 83 (63.8) |
| III + IV | 47 (36.2) |
| KRAS mutation | 48 (36.9) |
| BRAF V600E mutation | 5 (3.8) |
| TYMS LOH | 34 (26.2) |
| Overall survival | |
| Deaths n (%) | 45 (34.6) |
| Mean time month (95%CI) | 110.0 (99.5-120.5) |
| Disease-free survival | |
| Events n (%) | 51 (39.2) |
| Mean time month (95%CI) | 100.1 (88.3-112.0) |
| Median follow up in months (range) | 71.2 (0.5-156.8) |
- Citation: Ntavatzikos A, Spathis A, Patapis P, Machairas N, Vourli G, Peros G, Papadopoulos I, Panayiotides I, Koumarianou A. TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer. World J Gastrointest Oncol 2019; 11(7): 551-566
- URL: https://www.wjgnet.com/1948-5204/full/v11/i7/551.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v11.i7.551